We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+35.19%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$336M
AUM Growth
+$28.4M
Cap. Flow
-$47.2M
Cap. Flow %
-14.05%
Top 10 Hldgs %
56.86%
Holding
90
New
10
Increased
16
Reduced
26
Closed
16

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$4.4M
2
FLNA
Filana Therapeutics
FLNA
+$4.02M
3
VERO
Venus Concept
VERO
+$3.39M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.94M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$2.73M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$22.2M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$9.85M
3
FATE icon
Fate Therapeutics
FATE
+$6.46M
4
BEAT
BioTelemetry, Inc.
BEAT
+$2.89M
5
BPMC
Blueprint Medicines
BPMC
+$2.76M

Sector Composition

Rank Sector Weight
1 Healthcare 96.39%
2 Miscellaneous 3.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STXS icon
1
Stereotaxis
STXS
$145M
$69.6M 20.72%
13,680,554
– –
FATE icon
2
Fate Therapeutics
FATE
$291M
$30.4M 9.05%
334,360
-104,100
-24% -$6.46M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$23.2M 6.9%
206,911
-26,178
-11% -$2.76M
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$15.7M 4.67%
181,306
+23,000
+15% +$1.7M
DRNA
5
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$12.9M 3.85%
587,756
+133,520
+29% +$2.94M
NBIX icon
6
Neurocrine Biosciences
NBIX
$15.7B
$8.84M 2.63%
92,208
+2,000
+2% +$193K
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$7.96M 2.37%
80,375
+36,000
+81% +$4.4M
DXCM icon
8
DexCom
DXCM
$34.3B
$7.82M 2.33%
84,552
– –
ATRC icon
9
AtriCure
ATRC
$2.47B
$7.42M 2.21%
133,229
– –
IBB icon
10
iShares Biotechnology ETF
IBB
$10.5B
$7.18M 2.14%
47,400
-8,500
-15% -$1.21M
BHVN
11
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.04M 2.09%
82,100
-2,500
-3% -$212K
CSII
12
DELISTED
Cardiovascular Systems, Inc.
CSII
$6.62M 1.97%
151,200
– –
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.9M 1.76%
76,815
+1,000
+1% +$75K
XENE icon
14
Xenon Pharmaceuticals
XENE
$5.81B
$5.33M 1.59%
346,535
– –
PRQR icon
15
ProQR Therapeutics
PRQR
$323M
$5.2M 1.55%
1,237,400
– –
AFMD
16
DELISTED
Affimed
AFMD
$5.09M 1.51%
87,436
-4,992
-5% -$235K
STIM icon
17
Neuronetics
STIM
$224M
$4.93M 1.47%
443,717
-52,055
-10% -$391K
IDYA icon
18
IDEAYA Biosciences
IDYA
$3.87B
$4.64M 1.38%
331,661
– –
TBIO
19
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.15M 1.24%
225,393
+34,463
+18% +$617K
ARAY icon
20
Accuray
ARAY
$32.7M
$4.06M 1.21%
974,400
-99,900
-9% -$367K
TVRD
21
Tvardi Therapeutics
TVRD
$24.3M
$3.96M 1.18%
7,262
+390
+6% +$204K
AERI
22
DELISTED
Aerie Pharmaceuticals
AERI
$3.9M 1.16%
288,440
+4,000
+1% +$48.3K
ASND icon
23
Ascendis Pharma A/S
ASND
$16.3B
$3.88M 1.15%
23,237
-6,000
-21% -$992K
AGTC
24
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.69M 1.1%
903,429
-191,710
-18% -$942K
LMNX
25
DELISTED
Luminex Corp
LMNX
$3.56M 1.06%
154,091
– –
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, DAFNA Capital Management held 90 positions worth $336M, up 9.2% from $308M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

DAFNA Capital Management withdrew a net $47.2M in Q4 2020, closing 16 positions and reducing 26 holdings. Its most notable exit was Immunomedics Inc, an estimated $22.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in Filana Therapeutics worth $3.07M.

  • DAFNA Capital Management's largest Q4 2020 buy was Filana Therapeutics: 450,000 shares worth $3.07M.
  • DAFNA Capital Management added most to Lakefront Biotherapeutics American Depositary Shares in Q4 2020, an estimated $4.4M increase.
  • DAFNA Capital Management's biggest Q4 2020 reduction was Fate Therapeutics, cutting an estimated $6.46M.
  • DAFNA Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $22.2M.
  • DAFNA Capital Management's ten largest holdings make up 57% of its $336M portfolio in Q4 2020.
  • DAFNA Capital Management opened 10 new positions and closed 16 in Q4 2020.
  • DAFNA Capital Management's portfolio value rose 9.2% quarter-over-quarter to $336M.

Based on DAFNA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.